Published in Medicine and Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck KGaA.
Report 1: Data presented today at this year's American Society of Clinical Oncology (ASCO) meeting in Chicago show that a novel combination regimen based on Merck KGaA's oral 5-fluorouracil (5-FU) therapy UFT (tegafur-uracil) plus leucovorin (LV) has shown an excellent response rate in the first-line treatment of metastatic colorectal cancer (mCRC).
In the SCOUT study (Study of CPT-11 with Oxaliplatin combined with UFT plus leucovorin Therapy), the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.